Alnylam PharmD Fellowship Program

Alnylam Pharmaceuticals in partnership with Northeastern University, Bouvé College of Health Sciences

Program Guide and Application Information 2021-2023
A Message from Alnylam’s Leadership

Watching the Alnylam Fellowship Program expand since its inception five years ago has been truly remarkable. It has grown to involve multiple unique expertise areas, offering prospective fellows a diversity of experiences. For the biopharmaceutical industry, the fellowship allows us to develop a pipeline of top talent capable of tackling the complex challenges patients and their caregivers face every day. For Alnylam’s fellows, the opportunities here are limitless. The role of the fellow does not stop at the specific expertise area they are working in. Alnylam’s open-culture allows fellows to wear many different hats and explore interests in multiple expertise areas across the company.

Seeing our past fellows continue to serve the organization in various roles reflects the immense possibilities and gratifying work we do every day. At Alnylam, it is not only your degree or years of experience that dictate which roles and responsibilities you are able to take on. Rather, your skills, dedication, and commitment to patients are what allow you to thrive in this culture. My own professional trajectory is an example of this; I recently transitioned from a job I loved, serving as the Vice President of Medical Affairs, to becoming the General Manager of a late-stage pipeline program for a pediatric rare disease. As Alnylam evolves to becoming a global research, clinical development, and commercial company, I have no doubt that future fellows in the Alnylam Fellowship Program will continue to have unique, immersive, and unbounded experiences throughout their tenure.

Pritesh Gandhi, PharmD
General Manager, Lumasiran
Founder of the Alnylam/Northeastern Fellowship Program
# TABLE OF CONTENTS

## About Alnylam

- Company Overview ................................................................. 4
- Science and RNAi Platform ...................................................... 5

## The Alnylam Fellowship Program

- Fellowship Program Overview ............................................... 6
- Current Fellowships Recruiting ............................................... 7-12
  - Regulatory Affairs ................................................................. 7
  - Global Medical Affairs ........................................................... 8
  - Value & Evidence Strategy (VESt/HEOR) ................................. 9
  - Global Medical Information ..................................................... 10
  - Clinical Development ............................................................ 11
  - US Marketing ........................................................................... 12
- Past Fellows ............................................................................. 13

## Northeastern University

- Northeastern Fellowship .......................................................... 14
- Fellow Network/Life in Boston ................................................ 15

## Application Information

- Application Process ................................................................. 16
Founded in 2002, Alnylam Pharmaceuticals established an unwavering commitment to harnessing the power of RNA interference (RNAi) for treating rare conditions for patients with high unmet medical needs. Alnylam has lead the translation of RNAi to an innovative class of approved and investigational medicines used to treat a wide range of diseases using its powerful, clinically validated approach. In the summer of 2018, Alnylam established a new class of medicines, pioneering the delivery of RNAi therapeutics to patients through the FDA and EMA approval of ONPATTRO® (patisiran). This is the first of multiple launches anticipated in the “Alnylam P5x25” guidance for the advancement and commercialization of RNAi therapeutics. The passionate and dedicated employees at Alnylam look forward to delivering its medicines to patients who need them around the world.

COMPANY TRAJECTORY SNAPSHOT

Employees 19 Countries 11 Programs Currently in Clinical Development 4 Approved Products* >35 Clinical Studies to Date >8yrs Longest Duration of Exposure

We have been named a Top Place to Work 7x in a Row

The Boston Globe

Top Places to Work 2015–2021

“RNAi has been heralded as a major scientific breakthrough that happens once every decade or so.”

Phillip Sharp, Ph.D.
Noble Laureate & Founder of Alnylam
RNAi was first discovered in the purple petunia flower and later translated into worms by biologists Andrew Fire and Craig Mello, marking a major scientific breakthrough while establishing a new frontier in drug development. Alnylam’s mission is to build a top-tier biopharmaceutical company founded on RNAi. Rather than treating symptoms, Alnylam’s approved and pipeline of investigational therapies work upstream of today’s medicines by silencing the messenger RNA (mRNA) that is transcribed into disease-causing or disease-contributing proteins. Through RNAi, patients are treated in a fundamentally new way.

FROM POSSIBILITIES TO PATIENTS

ABOUT RNAi

NEW CLASS OF MEDICINES

ALNYLAM CLINICAL DEVELOPMENT PIPELINE

Focused in 4 Strategic Therapeutic Areas (STArs):

- Genetic Medicines
- Cardio-Metabolic Diseases
- Infectious Diseases
- CNS/Ocular Diseases

HUMAN POC BREAKTHROUGH DESIGNATION EARLY/MID STAGE (Phase 2/3 or Early Phase 3) LATE STAGE (Phase 3 or Late Phase 3) REGISTRATION/COMMERCIAL RIGHTS

ONPATTRO® (patisiran) 1 ATTR Amyloidosis-PN 2
global

GIVLAARI® (givosiran) 2 Acute Hepatic Porphyria 3
global

OXLUMO® (lumasiran) 3 Primary Hyperoxaluria Type 1 4
global

Leqvio® (inclisiran) 4 Hypercholesterolemia 5 Milestones & up to 20% Royalties 6

Vutrisiran ATTR Amyloidosis-PN 5 Global

Patisiran ATTR Amyloidosis Label Expansion 2 Global

Vutrisiran ATTR Amyloidosis 2 Global

Vutrisiran Stargardt Disease 2 Global

Fitzisiran Hemophilia 5 15-30% Royalties

Lumasiran Severe PHI Recurrent Renal Stones 5 Global

Comdisiran (+/ Pozelimab) 9 Complement-Mediated Diseases 2 50-50: Milestone/Royalty

Belcrasin® Alpha-1 Liver Disease 2 Ex-U.S. option post-Phase 3

ALN-HBV02 (VIR-2218) 8 Hepatitis B Virus Infection 2 50-50 option post-Phase 2

Zilebesiran (ALN-AGT) Hyperoxaluria 2 Global

ALN-HSD NASH 2 50-50

ALN-APP Alzheimer’s Disease; Cerebral Amyloid Angiopathy 2

ALN-XDH Gout 2

1 POC: proof of concept - defined as having demonstrated target gene knockdown and/or additional evidence of activity in clinical studies
2 Includes marketing application submissions
3 Approved in the U.S., Canada and Europe for the treatment of adults with familial Mediterranean fever
4 Approved in the U.S., for the treatment of adults with acute hepatic porphyria (AHP)
5 Approved in the EU and Japan for the treatment of AHP in adults and adolescents aged 12 years and older
6 Novartis has obtained global rights to develop, manufacture and commercialize inclisiran
7 50% of inclisiran royalty revenue from Novartis will be payable to Blackstone by Alnylam
8 Phase 3 study of vutrisiran in Stargardt Disease expected to initiate in late 2022
9 Cemdisiran and pozelimab are each currently in Phase 2 development; Alnylam and Regeneron are evaluating potential combinations of these two investigational therapeutics
10 Vir is leading and funding development of ALN-HBV02

As of April 2022
In 2015, Alnylam Pharmaceuticals partnered with Northeastern University to offer a unique fellowship opportunity in the heart of Boston. The program set out to equip postdoctoral PharmDs with the skills necessary to develop the advanced medicines of the future, like RNAi. The goal was and remains the same: to cultivate the future leaders of biotechnology and allow fellows to pioneer new therapies for patients. Alnylam fellows are grounded in their core expertise area but utilize the fellowship’s flexibility to branch out and discover other opportunities throughout the organization. Part of the backbone of the fellowship program is the Northeastern University teaching opportunities which allow fellows to share their knowledge in an educational setting.

WHAT SETS THE ALNYLAM/NORTHEASTERN FELLOWSHIP APART?
1. Ability to work in multiple therapeutic areas across pre-commercial, launch, and post-approval activities
2. Vested interest and individualized mentoring from leading professionals in their field
3. Opportunities to engage in immersive, personalized experiences inside and out of one’s expertise area
4. Ability to conduct academic research aligned with your interests under the mentorship of engaged Northeastern faculty members
5. Located in the heart of the world’s biotech hub, Cambridge, MA
Regulatory Affairs

ACTIVELY RECRUITING: 1 FELLOW

Regulatory Affairs at Alnylam is a group with diverse scientific, technical, and clinical expertise. The team is responsible for creating and implementing innovative global strategies for expedited drug development and approval of Alnylam’s products. All stages of drug development are dependent on effective regulatory support and management, including the generation and filing of investigational new drug applications, clinical trial applications, and marketing applications, continuing throughout Alnylam’s product life-cycle. Unique experiences in the rare disease space include orphan drug applications, breakthrough therapy, and PRIME designation requests, and other novel regulatory pathways and approaches.

ROLES AND RESPONSIBILITIES

- Working cross-functionally to support successful global regulatory submissions and filings
- Supporting, preparing and submitting international marketing authorization applications (e.g., MAAs, NDAs)
- Supporting the development and maintenance of regional labeling across programs
- Coordination and management activities with internal team and external consultants
- Regulatory annual report generation, management, and submission
- Critical analysis and presentation of regulatory intelligence and industry surveillance

How is the Alnylam fellowship unique from your perspective?

“To work with the teams that achieved approval for the first ever RNAi therapy - and that are continuing to bring this technology to patients with unmet needs - affords fellows the opportunity to gain hands-on regulatory experience in areas many do not encounter over the course of a career. This exciting time at Alnylam has already exposed me to products across all phases of development. I am confident the unparalleled experiences provided at Alnylam will serve as an incredible launch pad for a fulfilling career.”

Caitlin Albrecht, PharmD, 1st Year Regulatory Affairs Fellow

What did you learn in your first year on the job?

“I knew I liked regulatory affairs but didn’t realize how much I would genuinely enjoy the work I do every day. No day is the same, and there is always something new to stimulate my curiosity. I have been through a product launch, FDA and EMA filing, and new label development within the first year of my career.”

Farida Azizova-Such, PharmD, RPh, 2nd Year Regulatory Affairs Fellow

What characteristics do you believe define an Alnylam fellow?

“One is ‘insatiable curiosity’. This characteristic emanates throughout Alnylam and has helped the company make many scientific breakthroughs for patients. An Alnylam fellow should be insatiably curious about drug development, innovative science, and how all of this comes together in our submissions and interactions with Health Agencies. Another is being ‘team-oriented’. One of our core values is Commitment to People, including the diverse set of team members we work with daily from across different expertise areas. Drug development is a highly collaborative endeavor, and an Alnylam fellow will need to engage globally. This will provide skills and experiences to help in any career path they choose.”

Andrew Slugg, MS, MBA, Regulatory Affairs Preceptor & Senior Vice President of Regulatory Affairs
Global Medical Affairs

**ACTIVELY RECRUITING: 1 FELLOW**

The core responsibility of Medical Affairs at Alnylam is to advance medicines for patients with rare diseases. Medical Affairs achieves this through stakeholder engagement, dissemination of data, and providing education and support to healthcare professionals to enable diagnosis and improve the care of patients. Fellows can expect to drive Medical Affairs strategy through engaging cross-functional collaborations to advance RNAi therapeutics. This position is ideal for determined and adaptable individuals seeking unique experiences and professional growth within Global Medical Affairs.

**ROLES AND RESPONSIBILITIES**

- Creation of medical congress materials, including abstracts, presentations, and scientific symposia
- Support the development of comprehensive global publications
- Execution of scientific communication strategy from development to commercialization
- Engage with key opinion leaders to develop various medical communication and publication deliverables
- Collaboration with Commercial, Regulatory, and Clinical expertise areas
- Opportunities to expand to additional experiences tailored to your career goals

**Why did you choose Alnylam?**

“Alnylam drew me in with a powerful mission, dedicated core values, and really interesting science, but that was just the beginning for me. The more I learned about this organization, the more I realized how instrumental these components have been in the growth of the company and intriguing pipeline. It’s an honor to be a part of a company that is working day in and day out to make sure that revolutionary life-changing medications are brought to patients.”

Lauren Dodd, PharmD, 1st Year Medical Affairs Fellow

**What excites you about Alnylam’s pipeline?**

“Not only do I get to learn from and work with a new therapeutic class of medications, but the depth of Alnylam’s RNAi platform technology also provides me with opportunities to interact with products in different phases of the regulatory approval process. Understanding the intricate role Medical Affairs plays in these different instances is essential to growing my foundational knowledge that will set me up for a successful career.”

Katie Alfond, PharmD, RPh, 2nd Year Medical Affairs Fellow

**What is most rewarding about the fellowship and your role as a preceptor?**

“At Alnylam, fellows are not just an extension of our team; they are an integral part of our team. Fellows will have the unique opportunity to explore different career paths in depth to determine what they want to pursue following this two-year fellowship. While no two fellowship experiences are alike, I am here to guide the fellow in navigating opportunities to ensure they are on a path to success.”

Ilia Antonino, PharmD, MBA, Medical Affairs Preceptor & Director, Medical Communications and Publications
Value and Evidence Strategy (VESt)

Health Economics & Outcomes Research (HEOR)

ACTIVELY RECRUITING: 1 FELLOW

The purpose of the Value and Evidence Strategy team at Alnylam is to lead evidence generation and value demonstration activities through cross-functional collaboration with Clinical Development, Market Access, Market Insights, Field Medical, and other expertise areas. VESt’s goal is to ensure excellence in evidence generation to allow Alnylam’s innovative medicines to reach patients and healthcare systems. The fellow will develop a thorough understanding of and hands on experience in health economics and outcomes research methodologies through various research initiatives and recommended Master of Science coursework. The experience gained throughout this fellowship will allow the VESt Fellow to scientifically evaluate a therapeutic’s clinical, humanistic, and economic impact.

ROLES AND RESPONSIBILITIES

• Conducting evidence gap analysis and data generation strategy to communicate the value of Alnylam’s products
• Contributing to prospective and retrospective observational studies, cost-effectiveness analyses, comparative effectiveness research, chart review studies, claims analyses, patient-reported outcomes research, and other studies with potential for publication
• Conducting burden of illness studies, epidemiologic research, and pharmaco-economic analyses, as well as developing evidence dossiers for use by key healthcare decision makers
• Collaboration with peers/KOLs to obtain clinical input into evidence generation activities
• Leading a Medical Affairs product sub-team and participating in cross-functional working groups

How does the work of the fellow impact department-wide and company-wide goals?

“Fellows are key members responsible for projects that drive the company forward. From working on product launches and leading studies to presentations for key internal stakeholders, fellows get a breadth and depth of experience that not only supports their department and company goals, but also provides them with the experience to excel after their fellowship. Alnylam is growing exponentially; it’s a very exciting time to be a part of the company’s life.”

Siddharth Jain, PharmD, 1st Year Value and Evidence Strategy Fellow

What makes Alnylam stand out to you?

“Alnylam stands out for its deep pipeline, innovation, positive work culture, and location in Kendall Square (dubbed ‘the most innovative square mile on the planet’). Working to bring RNAi therapeutics, a new class of medicines, to patients with high unmet needs is both fast-paced and incredibly rewarding.”

John Ko, PharmD, MS, Director, Value & Evidence Strategy and Interim Global Medical Director

What are the learning opportunities in the VESt fellowship?

“VESt Fellows will take away far more than technical HEOR skills from this fellowship. Above all, my objective is to mentor the fellow to think critically to solve problems to meet patient needs. This skill will be crucial to one’s success in any future role.”

Sonalee Agarwal, BPharm, PhD, Vice President, Value and Evidence Strategy
Global Medical Information

ACTIVELY RECRUITING: 1 FELLOW

The Global Medical Information team serves to provide healthcare professionals, patients, and caregivers with balanced, accurate, and current medical information about Alnylam’s products. Medical Information engages cross functionally with other expertise areas such as Pharmacovigilance/Safety, Quality, Legal, Regulatory Affairs, Commercial, Clinical Operations, Clinical Development, and Information Technology, to ensure the safe, effective, and appropriate use of our therapies. Fellows in this program will partake in the development and launch of Medical Information services across the globe supporting multiple products. Furthermore, fellows sharpen their ability to read, interpret, and develop medical content accurately and fairly. While helping build the global medical information infrastructure to support Alnylam’s robust pipeline, the fellow will learn key project management skills as well.

ROLES AND RESPONSIBILITIES

- Global management of requests for medical information
- Medical Information content development, including standard response letters, custom response letters, and FAQs
- Adverse event and product quality complaint reporting
- Data analytics and insights collection and reporting
- Global product launch preparation and execution pertaining to medical information activities
- Support of medical congress and information booth

What is something that has surprised you about working at Alnylam?
“The authenticity and open culture of everyone I have interacted with has continuously blown me away. Team members consistently push me to ask questions, which helps solidify knowledge and growth as a fellow.”
Basia Zawadzki, PharmD, 1st Year Global Medical Information Fellow

What inspires you about Alnylam?
“Every single person at Alnylam works relentlessly to educate the community about the rare diseases we aim to treat and advocate for patients who otherwise have few or no treatment options. Their tremendous effort does not go unnoticed, and it inspires me every day.”
May Le, PharmD, 2nd Year Global Medical Information Fellow

Why should a fellowship candidate consider the medical information fellowship at Alnylam?
“The Alnylam Medical Information Fellowship is an unique experience in Medical Information and Medical Affairs. The Global Medical Information Fellow will have the opportunity to develop crucial skills and proficiencies for global medical information while learning in the dynamic and growing environment at Alnylam; a great combination for future success in the biotech and pharmaceutical industries.”
Rob Deering, PharmD, PhD, Global Medical Information Fellowship Preceptor & Sr. Manager, Medical Information
Clinical Development

ACTIVELY RECRUITING: 1 FELLOW

Clinical Development is the cornerstone of data generation in delivering novel medicines to patients. The Clinical Development fellowship at Alnylam will engage the fellow in work that is a fusion of scientific knowledge and operations of trial management to support clinical trial excellence. The fellow will start the fellowship in Clinical Operations, rotate through Clinical Research, and then have the option to select other expertise areas depending on the interests of the fellow. The intent of this program is to train fellows in comprehensive Clinical Development activities to build a foundation for roles as a clinical drug developer.

ROLES AND RESPONSIBILITIES

- Operational, technical, and scientific aspects of generating clinical development plans and clinical trial execution from startup through closeout, including management of contract research organizations (CROs) and vendors
- Development of key study documents, including protocol concepts and protocols (Phase I-III, natural history), data capture tools such as case report forms, procedure manuals, study operation plans, informed consent forms, clinical study reports, and IND/NDA submission documents
- Engagement in ongoing medical data review, analysis, and reporting of clinical information in materials for sites, investigators, and other stakeholders
- Planning and execution of investigator meetings and congresses to provide key messages about clinical trial data and study execution
- Participate in the development of effective working relationships with key investigators to optimize scientific quality/innovation of clinical study design, execution, reporting, and publication
- Process evaluation to ensure that all studies are conducted with the highest level of ethical and safety standards and in compliance with ICH/GCP guidelines and all applicable regulatory policies

What does Sense of Urgency mean to you and how do you live it at work?

“Sense of Urgency motivates the Alnylam Clinical Development team to improve the lives of patients with debilitating conditions. At Alnylam, we live a Sense of Urgency daily because our work contributes to the treatment of patients with unmet medical needs. I am motivated to work towards innovative solutions to challenges in clinical trials and contribute to the delivery of highly effective therapies for patients that would otherwise have limited treatment options.”

Thomas Solomon, PharmD, RPh, 1st Year Clinical Development Fellow

How does the work of the fellow impact department-wide and company-wide goals?

“Clinical Development Fellows at Alnylam hold positions of key responsibility. I am responsible for ensuring all aspects of the trial are executed including patient dosing, safety reporting, primary endpoint collection, and compliance with good clinical practice. Exceeding goals means potentially getting new drugs to market and expanding our treatment indications, which holds us accountable to the most important stakeholder: the patient.”

Joshua A. Emerson, PharmD, RPh, 2nd Year Clinical Development Fellow

Why is now the right time for a fellow to join Alnylam as the Clinical Development fellow?

“It is an incredible time in Alnylam Clinical Development. Your fellowship will allow experiences contributing to the first studies in uncharacterized diseases to global pivotal efficacy trials for registration. The Clinical Development Fellowship will uniquely provide a Fellow multi-faceted vision and vertical access on what it truly takes to bring a novel therapy from first-in-man through to regulatory approval at this innovative biopharmaceutical company. Are you ready to roll up your sleeves and dive in with us at Alnylam?”

Raina Gay Leahy, PhD, Clinical Development Fellowship Preceptor and Associate Director, Clinical Operations
US Marketing

ACTIVELY RECRUITING: 1 FELLOW

The US Marketing team is responsible for defining and executing the US marketing strategy of Alnylam’s RNAi therapeutics. Marketing achieves this through cross-functional collaboration with Medical Affairs, Regulatory Affairs, Clinical Development, and others. The US Marketing Fellow will engage in the execution of strategic brand plans and key marketing initiatives, launch of new RNAi therapeutics, and the generation of commercial insights. This fellowship is for individuals who are entrepreneurial, biased for action, and enjoy working in a dynamic business environment. The fellow will gain key experiences and skills in communication, commercial execution, marketing and strategic planning.

ROLES AND RESPONSIBILITIES

- Execution of personal promotion and targeted non-personal promotion tactics
- Creation of product value messaging and disease awareness materials to support field personnel
- Development of brand plan and brand positioning
- Cross-functional collaboration with Patient Services, Commercial Analytics, and US field teams to support launch activities
- Commercial activities at key conferences, including booth development, product theaters, and sponsorships
- Assessment of commercial opportunity and strategic fit of early pipeline assets including market sizing, competitive landscape scanning, target product concept development, and revenue forecasts

How have you been able to apply your PharmD training to a marketing role within the industry?

“In order to become a strong marketer, it’s crucial for me to understand the scientific background relating to the product and the target disease state. A PharmD graduate is prepared to take that scientific knowledge and translate it into key messages intended to raise disease state awareness and promote product education. It is up to us as marketers to communicate the value of our product so that patients get the proper treatment they need.”

Andrew Karaki, PharmD, 1st Year US Marketing Fellow

What initiatives have you been able to lead as a fellow?

“Christina and the US Marketing team care deeply about the fellows’ growth and development. Over the past year, I was able to pilot and lead social media efforts for ONPATTRO® (patisiran), be the commercial lead for several US conferences, and be project owner of a variety of materials for both patients and healthcare providers. I am excited for what’s to come in my 2nd year!”

David Iong, PharmD, 2nd Year US Marketing Fellow

Prior to coming to Alnylam, you completed a fellowship program yourself. How does this perspective play into your role as the US Marketing preceptor?

“I’m very grateful for my fellowship experience, and I try to emulate my previous preceptors when mentoring the US Marketing Fellows. I remember what it’s like to move to a new city and join a new company right after graduation, and I want every US Marketing Fellow to feel welcomed and integral to the team right from day 1. That means that our US Marketing Fellows are asked to own projects and contribute to our strategy from the very beginning. After all, the best way to learn is by doing!”

Christina Zhao, PharmD, US Marketing Fellowship Preceptor & Associate Director, US Marketing, TTR
Past Fellows

The Alnylam Fellowship Program is proud to be able to watch our fellowship alumni continue their professional development in key roles within the industry. The experiences and skills they gained during their fellowship tenure have become a launching pad for continued success and learning.

Alex Wei, PharmD  
2015-2017 Medical Affairs Fellow  
Current Role: Medical Director at SpoonfulOne

Dayna LeSueur, PharmD  
2016-2018 Regulatory Affairs Fellow  
Current Role: Clinical Research Scientist

Anastasia McManus, PharmD  
2016-2018 Medical Affairs Fellow  
Current Role: Senior Manager, Medical Communications

Ruthvik Malladi, PharmD  
2017-2019 Medical Affairs Fellow  
Current Role: Senior Manager, Medical Diagnosis

Madeline Merkel, PharmD  
2017-2019 Value & Evidence Strategy Fellow  
Current Role: Senior Manager, Value and Evidence Strategy

Sarah Scott, PharmD  
2017-2019 Regulatory Affairs Fellow  
Current Role: Manager, Regulatory Affairs

Caitlin Skenyon, PharmD, RPh  
2018-2020 Regulatory Affairs Fellow  
Current Role: Senior Regulatory Specialist, Regulatory Affairs

Jit Sheth, PharmD, RPh  
2018-2020 Global Medical Affairs Fellow  
Current Role: Medical Science Liaison

Stephen Meninger, PharmD  
2018-2020 Value & Evidence Strategy Fellow  
Current Role: Medical Affairs Manager, Value & Evidence Strategy

Ralph Reyes, PharmD, RPh  
2018-2020 Global Medical Information Fellow  
Current Role: Medical Science Liaison

Jessica Baldwin  
2019-2020 Value & Evidence Strategy Fellow  
Current Role: Manager, Global Health Economics and Outcomes Research at Vertex
Northeastern University is a global, experiential, research university built on a tradition of engagement with the world, creating a distinctive approach to education and research. At Northeastern, we encourage our students to become engaged, confident, and resourceful global citizens who realize their knowledge and actions have a far-reaching impact. Students ignite their passion for learning and are exposed to the endless possibilities around them through transformative experiential education.

The Northeastern University Fellowship Program provides a dynamic academic environment offering fellows the opportunity for a wide breadth of experiences:

- Develop teaching skills through participation in our Teaching and Learning Seminar series
- Facilitate small and large group didactic education in partnership with a faculty mentor
- Utilize a layered learning model in experiential education by co-precepting students on pharmacy practice experiences including Northeastern’s unique co-op program
- Create, present, and publish scholarly research through collaborative industry and university relationships
- Engage with faculty who participate in various interdisciplinary graduate programs including biotechnology, nanomedicine, immunology, health informatics, and drug discovery
- Network with local residents and other Northeastern fellows via professional development programs, teaching seminars, and participation on fellowship committees

Michael Conley
Associate Clinical Professor
Fellow Manager

Jason Lancaster
Clinical Professor
Fellow Manager

Debra Copeland
Associate Clinical Professor
Fellow Manager

Elizabeth Machart
Fellowship Program Manager

Mark Douglass
Associate Clinical Professor
Fellow Manager

Tayla Rose
Associate Clinical Professor
Fellow Manager

Michael Gonyeau
Clinical Professor
Fellow Manager

Andrew Orr-Skirvin
Clinical Professor
Fellowship Program Director

www.NUfellowship.com
Through these exciting partnerships, Northeastern fellows collaborate and learn from each other, further positioning them to be successful in both academic and industry settings. Fellows are empowered to shape their experience, as well as the future of the program, through leadership on the Professional Development & Networking and Recruitment committees.

**Life in Boston**
Northeastern University is in the heart of Boston, steps away from the famous Fenway Park and downtown Boston. Surrounded by top tier academic and research institutions, the area is home to pioneers of innovation who are committed to intellectual curiosity and scientific advancement. The greater Boston area is a cultural hub, offering world-class attractions and rich history.
Application Process

Launch your post-graduate career. Apply Now!

Fellows will be selected on a nationally competitive basis. All candidates must have a Doctor of Pharmacy degree from an ACPE-accredited college of pharmacy by June 30, 2021. Candidates must apply through the Northeastern website and are encouraged to do so by the priority application deadline of November 15, 2020. Please see the graphic below for more information on the application process.

Questions?
For more information and to apply:
Visit: www.NUfellowship.com
Email: PharmDfellowships@northeastern.edu

Address your cover letter and three letters of recommendation to:
J. Andrew Orr-Skirvin, Pharm.D., BCOP
Clinical Professor & Chair, Department of Pharmacy & Health System Sciences
Program Director, Pharmaceutical Industry Fellowships
Bouvé College of Health Sciences
360 Huntington Ave
140 The Fenway, R218
Boston, MA 02115

Email letters of recommendation to PharmDfellowships@northeastern.edu